Dublin's Full Health Medical Raises €3M to Take Its Clinical Screening Platform Beyond Ireland and the UK

Full Health Medical, a Dublin headquartered medtech company, has raised 3 million euros in a funding round led by Elkstone, with additional support from Enterprise Ireland and a group of strategic angel investors.

The company was founded in 2011 by Paul Carthy and Ann Shortt, and has spent more than a decade building a platform that manages the full logistics of health screening programmes while automating the clinical interpretation of the results those screenings produce. Rather than requiring a doctor to manually review and interpret every individual test result, Full Health Medical's platform runs consultant‑authored, clinically governed algorithms that automate that interpretation at scale, with every output fully auditable, according to the company. The system then translates the resulting clinical findings into plain‑language reports designed to help patients genuinely understand their own results, rather than receiving a raw set of biomarker figures with little context for what they actually mean.

That approach has produced substantial commercial traction over the company's fifteen years of operation. Full Health Medical says its platform has processed more than 500,000 medical screenings to date across its current markets of Ireland and the UK, with clients including Medmark, a provider of occupational health services. The scale of that screening volume, combined with the company's long operating history, gives Full Health Medical a considerably more mature customer base than many earlier‑stage health tech startups typically bring to a funding round of this size.

Elkstone co‑founder Alan Merriman, whose firm led the round, pointed directly to the specific bottleneck in healthcare delivery that Full Health Medical's technology addresses. "Full Health Medical is solving a genuine bottleneck in healthcare: the clinical expertise needed to interpret health data safely and at scale," Merriman said. "The team have built a platform that is both rigorously governed and genuinely scalable, and the results speak for themselves – half a million medicals processed to date, and a client base that already includes some of Ireland's largest population health programmes, and emerging international traction."

That combination of rigorous clinical governance and scalability sits at the center of what makes Full Health Medical's positioning distinct within a health tech landscape increasingly crowded with AI‑driven diagnostic and screening tools. Rather than replacing physician judgment outright, the platform is built to extend a doctor's clinical reasoning across a much larger volume of screenings than any individual physician could realistically review manually, while keeping every automated interpretation traceable back to algorithms that were authored and peer‑reviewed by practicing consultants. That governance layer matters particularly for large‑scale, employer‑sponsored or population‑level health screening programmes, where consistency, auditability, and regulatory defensibility carry as much weight as raw processing speed.

Full Health Medical's platform has evolved considerably since its founding, expanding from its original occupational health screening use case into a broader suite of tools spanning home test kit interpretation, population health reporting, and patient‑facing digital health assessment. During the Covid‑19 pandemic, the company adapted its existing "Flow" platform to incorporate coronavirus screening and triage capabilities, allowing doctors and other healthcare professionals to complete Covid‑19 assessments before proceeding to evaluate patients for other conditions, work the company said at the time helped free up between 50 and 75 percent of the procedural and administrative time GPs would otherwise have spent on manual screening and triage.

With the new capital, Full Health Medical plans to support its expansion into new markets outside of its established base in Ireland and the UK, building on what the company describes as emerging international traction beyond its home markets. The involvement of Enterprise Ireland alongside Elkstone in the round reflects a familiar pattern for Irish medtech companies reaching an inflection point in their growth, where state‑backed enterprise development funding is combined with private venture capital to support the specific costs, regulatory work, and market entry activities involved in expanding a clinically governed health platform into new geographies. Whether Full Health Medical can replicate the trust and scale it has built with large Irish and UK population health programmes in new international markets, each with their own distinct regulatory and clinical governance requirements for health data, will be the central test determining how far this latest round of funding ultimately takes the company.